Sensyne Health PLC (AIM:SENS) has agreed a deal with OMNY Health that gives it access to more than 22mln de-identified patient records held by the US firm.
It effectively doubles the dataset Sensyne has access to.
The UK group is at the cutting edge of data analysis and is using AI and machine learning to interrogate and analyse ethically-source patient records for findings that could aid drug development and/or help its health service partners.
Sensyne North America president, Derek Baird, said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries.
“The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.
“We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”
